ID
15365
Description
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01) https://clinicaltrials.gov/ct2/show/NCT02419378 Principal Investigator Prof. Dr. Dr. Sven Meuth, University Hospital Muenster, Germany
Link
https://clinicaltrials.gov/ct2/show/NCT02419378
Keywords
Versions (2)
- 2015-08-13 2015-08-13 - Martin Dugas
- 2016-05-28 2016-05-28 -
Uploaded on
28 maj 2016
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Adverse Event Multiple Sclerosis ALAIN01 NCT02419378
Adverse Event Multiple Sclerosis ALAIN01 NCT02419378
- StudyEvent: SE
Description
AERQG
Description
AE: Number
Data type
integer
Alias
- UMLS CUI [1]
- C2826275
Description
AE: Term
Data type
text
Alias
- UMLS CUI [1]
- C0877248
Description
AE: Start date
Data type
date
Alias
- UMLS CUI [1]
- C2697888
Description
AE: Serious event
Data type
text
Alias
- UMLS CUI [1]
- C1519255
Description
AE: Toxicity (CTCAE) Grade
Data type
text
Alias
- UMLS CUI [1]
- C2985911
Description
Adverse Event Attribution to Product or Procedure
Data type
text
Alias
- UMLS CUI [1]
- C1510821
Description
AE: Action taken with study treatment
Data type
text
Alias
- UMLS CUI [1]
- C2981656
Description
AE: End date
Data type
date
Alias
- UMLS CUI [1]
- C2697886
Description
AE: Ongoing
Data type
text
Alias
- UMLS CUI [1]
- C2826663
Description
AE: Outcome
Data type
text
Alias
- UMLS CUI [1]
- C1705586
Similar models
Adverse Event Multiple Sclerosis ALAIN01 NCT02419378
- StudyEvent: SE
C0011008 (UMLS CUI [1,2])